RDY Retained Earnings vs Short Long Term Debt Total Analysis
RDY Stock | USD 69.98 0.81 1.17% |
Dr Reddys financial indicator trend analysis is much more than just examining Dr Reddys Laboratories latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dr Reddys Laboratories is a good investment. Please check the relationship between Dr Reddys Retained Earnings and its Short Long Term Debt Total accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Retained Earnings vs Short Long Term Debt Total
Retained Earnings vs Short Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Dr Reddys Laboratories Retained Earnings account and Short Long Term Debt Total. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Dr Reddys' Retained Earnings and Short Long Term Debt Total is -0.33. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Dr Reddys Laboratories, assuming nothing else is changed. The correlation between historical values of Dr Reddys' Retained Earnings and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Dr Reddys Laboratories are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Retained Earnings i.e., Dr Reddys' Retained Earnings and Short Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | -0.33 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Short Long Term Debt Total
Most indicators from Dr Reddys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Dr Reddys Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. At this time, Dr Reddys' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 740.6 B in 2024, whereas Selling General Administrative is likely to drop slightly above 39.7 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 113.8B | 203.0B | 233.4B | 245.1B | Total Revenue | 214.4B | 245.9B | 282.8B | 296.9B |
Dr Reddys fundamental ratios Correlations
Click cells to compare fundamentals
Dr Reddys Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Dr Reddys fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 232.2B | 265.5B | 296.7B | 322.9B | 371.3B | 206.1B | |
Other Current Liab | 39.4B | 33.5B | 41.6B | 48.9B | 56.2B | 59.0B | |
Total Current Liabilities | 72.8B | 81.5B | 97.8B | 85.7B | 98.6B | 68.3B | |
Total Stockholder Equity | 155.0B | 175.0B | 190.5B | 232.9B | 267.8B | 281.2B | |
Retained Earnings | 144.2B | 157.9B | 175.7B | 215.6B | 247.9B | 260.3B | |
Accounts Payable | 10.7B | 21.9B | 25.6B | 22.7B | 26.1B | 15.0B | |
Cash | 2.1B | 14.8B | 14.9B | 5.8B | 6.6B | 6.3B | |
Other Assets | 14.8B | 11.6B | 13.7B | 7.1B | 8.2B | 8.6B | |
Short Term Investments | 23.7B | 19.7B | 29.5B | 61.0B | 70.1B | 73.6B | |
Inventory | 35.1B | 45.4B | 50.9B | 48.7B | 56.0B | 30.4B | |
Total Liab | 77.3B | 90.5B | 106.1B | 90.0B | 103.5B | 88.4B | |
Intangible Assets | 27.7B | 35.6B | 27.2B | 30.7B | 35.3B | 24.0B | |
Property Plant Equipment | 52.3B | 57.1B | 62.2B | 66.3B | 76.2B | 80.1B | |
Short Long Term Debt Total | 22.1B | 30.3B | 33.8B | 13.5B | 15.5B | 14.7B | |
Other Liab | 3.5B | 3.1B | 2.7B | 2.5B | 2.9B | 3.1B | |
Property Plant And Equipment Net | 52.3B | 57.1B | 62.2B | 56.5B | 65.0B | 54.0B | |
Current Deferred Revenue | 1.9B | 2.0B | 2.6B | 2.0B | 1.8B | 1.7B | |
Net Debt | 20.0B | 15.5B | 19.0B | 7.7B | 8.8B | 8.4B | |
Non Current Assets Total | 101.9B | 117.2B | 115.5B | 118.6B | 136.4B | 95.9B | |
Non Currrent Assets Other | 2.6B | 952M | 948M | 12.7B | 14.6B | 15.4B | |
Cash And Short Term Investments | 25.7B | 34.6B | 44.4B | 66.7B | 76.8B | 80.6B | |
Net Receivables | 61.8B | 52.4B | 70.0B | 72.5B | 83.4B | 46.9B | |
Good Will | 4.0B | 4.6B | 4.4B | 5.5B | 6.3B | 6.6B | |
Common Stock Shares Outstanding | 166.1M | 166.3M | 166.3M | 166.4M | 191.3M | 175.2M | |
Liabilities And Stockholders Equity | 232.2B | 265.5B | 296.7B | 322.9B | 371.3B | 215.0B | |
Non Current Liabilities Total | 4.4B | 9.0B | 8.3B | 4.3B | 4.9B | 4.7B | |
Other Current Assets | 5.8B | 14.5B | 13.9B | 15.1B | 17.4B | 9.8B | |
Other Stockholder Equity | 7.5B | 14.9B | 12.9B | 15.2B | 17.4B | 13.2B | |
Total Current Assets | 130.4B | 148.2B | 181.1B | 204.3B | 234.9B | 120.7B | |
Accumulated Other Comprehensive Income | 2.4B | 1.3B | 1.1B | 1.3B | 1.5B | 1.4B | |
Short Term Debt | 20.8B | 24.0B | 28.1B | 12.2B | 14.0B | 27.5B | |
Property Plant And Equipment Gross | 52.3B | 57.1B | 142.0B | 152.3B | 137.0B | 130.2B | |
Net Tangible Assets | 91.9B | 123.3B | 134.8B | 158.9B | 182.7B | 102.9B | |
Long Term Investments | 3.1B | 8.3B | 8.0B | 6.1B | 7.0B | 4.5B | |
Short Long Term Debt | 20.3B | 24.0B | 28.1B | 12.2B | 11.0B | 17.2B | |
Long Term Debt Total | 1.3B | 6.3B | 5.7B | 1.3B | 1.2B | 1.1B |
Currently Active Assets on Macroaxis
XERS | Xeris Pharmaceuticals | |
IGM | iShares Expanded Tech | |
QCOM | Qualcomm Incorporated | |
QTEC | First Trust NASDAQ 100 Technology | |
BA | The Boeing |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.36 | Dividend Share 40 | Earnings Share 4.01 | Revenue Per Share 280.1794 | Quarterly Revenue Growth 0.125 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.